- Home
- SAVA
as 01-17-2025 4:00pm EST
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 135.9M | IPO Year: | N/A |
| Target Price: | $111.50 | AVG Volume (30 days): | 3.4M |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.37 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.23 - $42.20 | Next Earning Date: | 02-26-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Cassava Sciences Inc. News
SAVA Breaking Stock News: Dive into SAVA Ticker-Specific Updates for Smart Investing
MT Newswires
11 days ago
Cassava Sciences to Reduce Staff, Halt Further Analysis
GlobeNewswire
12 days ago
Cassava Sciences Provides a Business Update
Zacks
2 months ago
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More
Zacks
2 months ago
A Post-Mortem on Cassava Sciences
Zacks
2 months ago
SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage Study
Zacks
2 months ago
Down -83.93% in 4 Weeks, Here's Why You Should You Buy the Dip in Cassava Sciences (SAVA)
MT Newswires
2 months ago
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Tuesday; Cassava Sciences to Advance, MicroStrategy to Decline
Investor's Business Daily
2 months ago
Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops
Compare SAVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SAVA Cassava Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.